http://www.ncbi.nlm.nih.gov/pubmed/?term=A+Multicenter+Randomized+Double-Blind+Parallel-Group+Placebo-Controlled+Study+of+the+Effects+of+Qili+Qiangxin+Capsules+in+Patients+with+Chronic+Heart+Failure.

http://www.ncbi.nlm.nih.gov/pubmed/?term=A+Multicenter+Randomized+Double-Blind+Parallel-Group+Placebo-Controlled+Study+of+the+Effects+of+Qili+Qiangxin+Capsules+in+Patients+with+Chronic+Heart+Failure.

Multicenter Randomized Double-Blind Parallel-Group Placebo-Controlled Study of the Effects of Qili Qiangxin Capsulesin Patients with Chronic Heart Failure.

Li X, Zhang J, Huang J, Ma A, Yang J, Li W, Wu Z, Yao C, Zhang Y, Yao W, Zhang B, Gao R.

J Am Coll Cardiol. 2013 Jun 6. doi:pii: S0735-1097(13)02178-5. 10.1016/j.jacc.2013.05.035. [Epub ahead of print   

PMID: 23747768

 

 

Abstract

OBJECTIVES:

The purpose of this study was to assess the effects of Qili Qiangxin capsules in patients with chronic heart failure (CHF).

BACKGROUND:

Qili Qiangxin capsules are a traditional Chinese medicine (TCM) that has been approved for the treatment of CHF, but the evidence supporting its efficacy remains unclear.

METHODS:

A total of 512 CHF patients were enrolled and randomly assigned to receive the placebo or Qili Qiangxin capsules in addition to their standard medications for the treatment of CHF. The primary endpoint was the reduction or percent change in the plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) level during 12 weeks of treatment.

RESULTS:

At the 12-week follow-up, a significant reduction in the NT-proBNP level from baseline was observed in both groups, but the QiliQiangxin capsule group demonstrated a significantly greater reduction than the placebo group (p = 0.002); 47.95% of patients in the QiliQiangxin capsule group demonstrated reductions in NT-proBNP of at least 30% compared to 31.98% of patients in the placebo group (p < 0.001). Treatment with Qili Qiangxin capsules also demonstrated superior performance in comparison to the placebo with respect to New YorkHeart Association (NYHA) functional classification, left ventricular ejection fraction (LVEF), 6-minute walking distance (6MWD) and quality of life.

CONCLUSIONS:

On a background of standard treatment, Qili Qiangxin capsules further reduced the levels of NT-proBNP. Together, our data suggest that Qili Qiangxin capsules could be used in combination therapy for CHF.

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: